高感度の小児における腎移植前のイムリフィダーゼ (DINKY)
イムリフィダーゼ治療後に陰性に変換された生きているドナーまたは死亡したドナーに対して陽性のクロスマッチを伴う腎移植を受ける、非常に敏感な子供(1〜17歳)におけるイムリフィダーゼの有効性と安全性を評価するための単群多施設試験
The goal of this clinical trial is to learn about the efficacy and safety of imlifidase in highly sensitized paediatric patients, 1-17 years old, with end stage renal disease (ESRD).
The main questions it aims to answer are:
- Does imlifidase treatment result in crossmatch conversion that enables transplantation?
- How is the function of the transplanted kidney?
The participants will be hospitalised in accordance with the normal routines for transplanted patients. The patients will receive medication to prevent rejection of the donor kidney, and because such treatment make the body more vulnerable medications to prevent infections.
調査の概要
詳細な説明
After being informed about the study and potential risks, all patients giving written informed consent will undergo pre-screening to determine eligibility for study entry.
The trial will include highly sensitised ESRD paediatric patients (1-17 years). The patients have previously undergone desensitization unsuccessfully or have an anti-HLA antibody status deemed too difficult to make a successful desensitization using other experimental methods.
A screening visit will take place when an organ offer has been placed for a final check of the patients' eligibility for study participation.
All patients included in the trial will be desensitized with imlifidase to convert the positive XM to negative and then transplanted with either a kidney from a deceased donor (DD) or a living donor (LD).
Patients will be hospitalised in accordance with the normal routines for transplanted patients at each clinic.
Following transplantation, the patients will receive induction therapies, rejection prophylaxis, and maintenance immunosuppressive therapies.
The patients will be closely monitored for any signs of antibody-mediated rejections (AMRs).
The duration of the interventional trial period after an organ has been offered will be 6 months for each patient. The trial includes a follow-up part to collect long-term efficacy and safety data up to 5 years after the transplantation.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Central Contact
- 電話番号:+46 46 16 56 70
- メール:clinicalstudyinfo@hansabiopharma.com
研究場所
-
-
-
London、イギリス、WC1N 3JH
- 募集
- Great Ormond Street Hospital for Children NHS Foundation Trust
-
コンタクト:
- S Marks, MD
-
主任研究者:
- S Marks, MD
-
-
-
-
-
Rome、イタリア、00165
- まだ募集していません
- Ospedale Pediatrico Bambino Gesu
-
コンタクト:
- Raffaella Labbadia, MD
- メール:ctc@opbg.net
-
主任研究者:
- Raffaella Labbadia, MD
-
-
-
-
Stockholm County
-
Huddinge、Stockholm County、スウェーデン、SE-141 86
- 募集
- Karolinska University Hospital
-
コンタクト:
- L Wennberg, MD
- メール:Lars.Wennberg@regionstockholm.se
-
主任研究者:
- L Wennberg, MD
-
-
-
-
-
Barcelona、スペイン、08035
- 募集
- Hospital Unviersitari Vall d'Hebron, Nefrología Pediátrica
-
主任研究者:
- Gema Ariceta, MD
-
コンタクト:
- Gema Ariceta, MD
- メール:gema.ariceta@vallhebron.cat
-
Barcelona、スペイン、08950
- まだ募集していません
- Hospital Sant Joan De Deu Barcelona
-
コンタクト:
- Yolanda Calzada, MD
- メール:frecerca.startup@sjd.es
-
主任研究者:
- Yolanda Calzada, MD
-
-
-
-
-
Helsinki、フィンランド、00290
- 引きこもった
- HUS, Helsinki University Hospital
-
-
-
-
-
Paris、フランス、75019
- 募集
- Robert Debre University Hospital
-
コンタクト:
- Julien Hogan, Professor
- メール:julien.hogan2@aphp.fr
-
主任研究者:
- Julien Hogan, Professor
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Signed Informed Consent obtained from patient/parent/legal guardian/independent witness (depending on patient's age) before any trial-related procedures
- Highly sensitised patient with panel reactive antibodies (PRA) ≥80%
- Male or female patient between the age of 1 to 17 years (up to the day before the 18th birthday) at the time of screening
- Patient with end-stage renal disease (ESRD) and waiting for a renal transplant from a living or deceased donor
- Patient must be transplantable (including size mismatch) at the time of obtaining informed consent for trial participation
- Patients who have previously undergone desensitisation unsuccessfully with plasmapheresis/IVIg/anti-CD20 or have an anti-HLA antibody status deemed too difficult to make a successful desensitisation (judgement based on physicians' previous experience with similar patients)
- Positive crossmatch (XM) test determined by flow cytometry crossmatch (FCXM) and/or complement-dependent cytotoxicity crossmatch (CDCXM) tests against the donor. For the DD patients, if physical XM tests are not practically possible due to lack of time, patients may be included on a virtual crossmatch (vXM) predictive of a positive XM test.
- Willingness and ability to comply with the protocol as judged by the investigator
Exclusion Criteria:
- Previous treatment with imlifidase
- IVIg treatment within 28 days prior to imlifidase treatment
- Desensitisation treatment(s) within 1 month prior to the current transplantation
- Hypersensitivity to the active substance (imlifidase) or to any of the excipients and to other immunosuppressive drugs specified in the protocol
- Ongoing serious infections
- Present, or history of, thrombotic thrombocytopenic purpura (TTP), or known familial history of TTP
- At the time of transplantation: severe other condition requiring treatment and close monitoring e.g. cardiac failure ≥ grade 4 (New York Heart Association), unstable coronary disease, active peripheral vascular disease, proven hypercoagulable conditions/events or oxygen dependent respiratory disease
- Malignancy within 3 years prior to transplantation
- ABO blood group incompatible transplantations (A2 and A2B kidneys will not be accepted for B recipients)
- Any other reason that, in the view of the investigator, precludes transplantation
- Breast feeding or pregnancy, if applicable
- Woman of fertile age and sexually active without adequate contraceptive measures to avoid pregnancy during the interventional trial period (i.e. up to 6 months after transplantation)
- Suspicion of Covid-19 infection or positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test
- Positive serology for human immunodeficiency virus (HIV)
- Clinical signs of hepatitis B virus (HBV), hepatitis C virus (HCV), cytomegalovirus (CMV), or Epstein Barr virus (EBV) infection
- Donor with positive serology for HIV, HBV, HCV or CMV to a patient with negative serology (mismatch serology). Mismatch serology for EBV in accordance with center specific standard procedures for transplantation of EBV negative recipients and at investigator's discretion.
- Clinically relevant active infection(s) as judged by the investigator
- Tuberculosis or history of tuberculosis
- Use of other investigational agents within 5 terminal elimination half-lives prior to the transplantation
- Contemporaneous participation in medical device studies
- Known mental incapacity or language barriers precluding patients'/parents'/legal guardians' adequate understanding of the informed consent information and the trial activities
- Inability by the judgement of the investigator to participate in the trial for any other reason
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Imlifidase
Imlifidase is administered intravenously as one infusion of 0.25 mg/kg over 15 minutes within 24 hours prior to transplantation. |
Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of patients with conversion of a positive crossmatch test to negative within 24 hours after start of imlifidase treatment
時間枠:From start of imlifidase administration to 24 hours
|
Immunoglobulins (IgG) including donor specific antibodies (DSAs) are rapidly and efficiently cleaved by imlifidase. A conversion of a positive to a negative XM will enable transplantation. |
From start of imlifidase administration to 24 hours
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
移植後5年までの移植片生存(死亡打ち切り)
時間枠:6ヶ月から5年まで
|
6ヶ月から5年まで
|
|
|
移植後5年までの移植失敗なしの生存
時間枠:6ヶ月から5年まで
|
6ヶ月から5年まで
|
|
|
移植後5年までの患者生存
時間枠:6ヶ月から5年まで
|
6ヶ月から5年まで
|
|
|
移植後5年までの透析依存患者の割合
時間枠:6ヶ月から5年まで
|
6ヶ月から5年まで
|
|
|
Renal function up to 5 years after transplantation as assessed by estimated glomerular filtration rate (eGFR)
時間枠:From pre-dose imlifidase up to 5 years
|
eGFR is a measure of kidney function. Reduced kidney function is characterised by a decreased eGFR value. |
From pre-dose imlifidase up to 5 years
|
|
Renal function up to 5 years after transplantation as assessed by serum/plasma creatinine levels
時間枠:From pre-dose imlifidase up to 5 years
|
Creatinine is a measure of kidney function. Reduced kidney function is characterised by an increased value. |
From pre-dose imlifidase up to 5 years
|
|
Renal function up to 5 years after transplantation as assessed by serum/plasma cystatin C levels
時間枠:From pre-dose imlifidase up to 5 years
|
Cystatin C is a measure of kidney function. Reduced kidney function is characterised by an increased value. |
From pre-dose imlifidase up to 5 years
|
|
Renal function up to 5 years after transplantation as assessed by proteinuria
時間枠:From pre-dose imlifidase up to 5 years
|
Proteinuria (protein/creatinine ratio in urine) is a measure of kidney function. Reduced kidney function is characterised by an increased value. |
From pre-dose imlifidase up to 5 years
|
|
DSA levels up to 5 years after transplantation
時間枠:From pre-dose imlifidase up to 5 years
|
Donor specific antibodies (DSAs) are antibodies in the recipient directed against the transplanted organ. |
From pre-dose imlifidase up to 5 years
|
|
Frequency of delayed graft function (DGF)
時間枠:From transplantation up 7 days after transplantation
|
DGF is defined as 'Need for dialysis within 7 days of transplantation' in "Delayed graft function in kidney transplantation: developing drugs for prevention, guidance for industry", FDA 2019. Frequency of patients having DGF in accordance with this definition will be presented. |
From transplantation up 7 days after transplantation
|
|
Length of DGF
時間枠:From transplantation up 7 days after transplantation
|
DGF is defined as 'Need for dialysis within 7 days of transplantation' in "Delayed graft function in kidney transplantation: developing drugs for prevention, guidance for industry", FDA 2019. The duration of DGFs in accordance with this definition will be presented. |
From transplantation up 7 days after transplantation
|
|
Imlifidase Pharmacokinetics (AUC)
時間枠:From pre-dose imlifidase up to Day 15
|
AUC = Area under the imlifidase plasma concentration versus time curve. |
From pre-dose imlifidase up to Day 15
|
|
Imlifidase Pharmacokinetics (Cmax)
時間枠:From pre-dose imlifidase up to Day 15
|
Cmax = Maximum observed plasma concentration of imlifidase following dosing. |
From pre-dose imlifidase up to Day 15
|
|
Imlifidase Pharmacokinetics (tmax)
時間枠:From pre-dose imlifidase up to Day 15
|
tmax = Time point for maximum observed plasma concentration of imlifidase following dosing |
From pre-dose imlifidase up to Day 15
|
|
Imlifidase Pharmacokinetics (t1/2)
時間枠:From pre-dose imlifidase up to Day 15
|
t1/2 = Terminal half-life of imlifidase. |
From pre-dose imlifidase up to Day 15
|
|
Imlifidase Pharmacokinetics (CL)
時間枠:From pre-dose imlifidase up to Day 15
|
CL = Clearance of imlifidase. |
From pre-dose imlifidase up to Day 15
|
|
Imlifidase Pharmacokinetics (Vz)
時間枠:From pre-dose imlifidase up to Day 15
|
Vz = Volume of distribution during the elimination phase |
From pre-dose imlifidase up to Day 15
|
|
Imlifidase Pharmacodynamic (PD) profile up to 9 days after imlifidase treatment
時間枠:From pre-dose imlifidase up to Day 10
|
PD is assessed as serum concentrations of intact IgG and its fractions following infusion. |
From pre-dose imlifidase up to Day 10
|
|
Immunogenicity profile of imlifidase up to 5 years after imlifidase treatment
時間枠:From pre-dose imlifidase up to 5 years
|
Immunogenicity is assessed as serum concentration of anti-imlifidase IgG (ADA). |
From pre-dose imlifidase up to 5 years
|
|
Proportion of patients with biopsy- and serology (DSA)-confirmed AMR up to 5 years after transplantation
時間枠:From transplantation up to 5 years
|
Banff scores (Loupy et al. 2020) will be used for biopsy evaluation. |
From transplantation up to 5 years
|
|
Proportion of patients with biopsy confirmed cell-mediated rejection (CMR) up to 5 years after transplantation
時間枠:From transplantation up to 5 years
|
Banff scores (Loupy et al. 2020) will be used for biopsy evaluation. |
From transplantation up to 5 years
|
その他の成果指標
結果測定 |
時間枠 |
|---|---|
|
イムリフィダーゼ注入後 48 時間以内に注入関連反応を起こした患者の割合として評価される安全性
時間枠:イムリフィダーゼ注入開始から48時間まで
|
イムリフィダーゼ注入開始から48時間まで
|
|
イムリフィダーゼ治療後30日以内に重度または重度の感染症の患者の割合として評価された安全性
時間枠:イムリフィダーゼ注入の開始から最大30日まで
|
イムリフィダーゼ注入の開始から最大30日まで
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Clinical Operations、Hansa Biopharma AB
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 20-HMedIdes-21
- 2022-500230-28-00 (その他の識別子:EU Trial Number)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。